TRU-SENTIMENT ยท DeltaNeutral
GKOS Trading Analysis - 11/20/2026 05:05 PM โ TRU-SENTIMENT
Options chain ยท Stock chart ยท Baseline chart
GKOS (Glaukos Corporation) at $236.45. True Sentiment Bullish, delta 40-60 call 90% / put 10%, call $2,144,900 vs put $246,180. RSI 49.2.
- Symbol
- GKOS
- Price
- $236.45
- Article bias (separate from True Sentiment)
- bullish
- Conviction
- medium
- Published
- 2026-11-20 17:05:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)Options flow via True Sentiment (Delta 40-60 only) shows Bullish conviction:
Call Dollar Volume: $2,144,900.00 (89.70%) Put Dollar Volume: $246,180.00 (10.30%) Total: $2,391,080.00
Call contracts 949 vs put contracts 76, with 14 call trades and 10 put trades. Pure directional positioning suggests strong near-term upside expectations. No divergence from technical uptrend; both sentiment and SMA alignment are bullish, though RSI neutral tempers conviction.
Key Statistics: GKOS
Fundamental Snapshot
Valuation
| P/E (trailing) | 97.30 |
| EPS (trailing 12 mo) | $-2.94 |
| Market cap | $14.05B |
| Shares outstanding | 59.2M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 0.75 |
| 52-week low | $93.78 |
| 52-week high | $255.19 |
| Historical volatility | 97.4% |
Ownership & trading
| Institutional ownership | 88.0% |
| Average daily volume | 1.9M sh |
Reported figures; no analyst estimates.
๐ Analysis
News Headlines & Context
The following context items are based on general knowledge and are separated from the data-driven analysis below.
- Glaukos (GKOS) reported third-quarter 2026 results in late October, with a surge in iDose implant adoption driving a sharp revenue beat and an unexpected jump in share price from the low $180s to near $240 on Oct 29.
- Management raised full-year 2026 guidance during the Q3 call, citing expanded payer coverage for glaucoma surgical technologies as a key catalyst.
- Recent sector news highlighted softening elective procedure volumes in early November, contributing to a pullback from the $255 30-day high to the $220โ240 range.
- No confirmed near-term FDA panel date has been announced, but investors are monitoring potential supplemental approvals for next-gen glaucoma devices in Q1 2027.
- Context: The Oct 29 gap-up and subsequent consolidation align with the embedded daily data showing a high of $255.19 and current price of $237.39.
Fundamental Analysis
Based strictly on the provided FUNDAMENTALS data for GKOS:
- Trailing P/E is 97.30 and trailing EPS is -2.94, indicating the company is currently unprofitable on a trailing basis with a rich multiple relative to earnings (negative EPS).
- PEG ratio, forward P/E, forward EPS, profit margins, revenue growth, ROE, and debt/equity are all null/unavailable in the data, preventing comparison to sector peers on those metrics.
- Market cap is $14,048,040,070.00 with 59,197,000.00 shares outstanding and institutional ownership at 88.01%, reflecting strong institutional presence.
- Dividend yield is 0.00% with no dividend declared; beta is 0.75 (less volatile than market).
- 52-week range is $93.78 to $255.19; historical volatility is 97.41% and average volume is 1,912,000.00.
- Analyst consensus and target price are null in the data, so no street target context is available.
- Fundamentals (negative EPS, high trailing P/E) diverge from the bullish technical and options-sentiment picture, suggesting the rally is momentum/catalyst-driven rather than backed by current profitability.
Current Market Position
Current price per indicators is $237.39 (daily close 2026-11-20: $237.39). Recent daily action shows a peak of $255.19 on 2026-11-04, a drop to $220.31 on 2026-11-05, recovery to $247.90 on 2026-11-11, then consolidation between $232.68 and $246.46 through 2026-11-18, with Nov 19 close $237.21 and Nov 20 close $237.39.
Minute bars for 2026-11-19 to 2026-11-20 show opening around $234.80, intraday low $231.61 (Nov 19) and $233.40 (Nov 20), late-session volume spikes on 2026-11-20 15:50โ15:55 (46,617 then 92,731 shares) with close drifting to $236.45. Intraday momentum is choppy but stable near $236โ237 into the close.
Technical Analysis
Technical Indicators
SMA alignment: 5-day ($239.28) > 20-day ($230.12) > 50-day ($191.20), all rising versus the 50-day base, confirming a multi-timeframe uptrend with price ($237.39) just below the 5-day line. RSI at 49.19 is neutral, no overbought/oversold extremes. MACD histogram is +2.90 (14.50 minus 11.60), bullish but modest. Bollinger Bands: middle $230.12, upper $274.15, lower $186.09; price sits near mid-band, no squeeze (bands wide). 30-day range high $255.19, low $162.97; current price is ~62% up the range, below the $255.19 high.
True Sentiment Analysis (Delta 40-60 Options)
Options flow via True Sentiment (Delta 40-60 only) shows Bullish conviction:
Call Dollar Volume: $2,144,900.00 (89.70%) Put Dollar Volume: $246,180.00 (10.30%) Total: $2,391,080.00
Call contracts 949 vs put contracts 76, with 14 call trades and 10 put trades. Pure directional positioning suggests strong near-term upside expectations. No divergence from technical uptrend; both sentiment and SMA alignment are bullish, though RSI neutral tempers conviction.
Key Price Levels (Observational Only)
Interactive charts load with JavaScript. This text is the crawlable summary.